Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Shahda S, Loehrer PJ, Clark RS, Spittler AJ, Althouse SK, Chiorean EG.

Oncologist. 2016 Jun;21(6):664-5. doi: 10.1634/theoncologist.2016-0071. Epub 2016 Jun 2.

2.

Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus.

Lu Y, Parker N, Kleindl PJ, Cross VA, Wollak K, Westrick E, Stinnette TW, Gehrke MA, Wang K, Santhapuram HK, You F, Hahn SJ, Vaughn JF, Klein PJ, Vlahov IR, Low PS, Leamon CP.

Mol Med. 2015 Jul 8;21:584-96. doi: 10.2119/molmed.2015.00040.

3.

Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.

Vergote I, Leamon CP.

Ther Adv Med Oncol. 2015 Jul;7(4):206-18. doi: 10.1177/1758834015584763. Review.

4.

Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate.

Lu Y, Stinnette TW, Westrick E, Klein PJ, Gehrke MA, Cross VA, Vlahov IR, Low PS, Leamon CP.

Arthritis Res Ther. 2011 Apr 4;13(2):R56. doi: 10.1186/ar3304.

5.

Strategy to prevent drug-related hypersensitivity in folate-targeted hapten immunotherapy of cancer.

Lu Y, Klein PJ, Westrick E, Xu LC, Santhapuram HK, Bloomfield A, Howard SJ, Vlahov IR, Ellis PR, Low PS, Leamon CP.

AAPS J. 2009 Sep;11(3):628-38. doi: 10.1208/s12248-009-9139-7.

6.

Issues related to targeted delivery of proteins and peptides.

Lu Y, Yang J, Sega E.

AAPS J. 2006 Jul 21;8(3):E466-78. Review.

Supplemental Content

Loading ...
Support Center